Blog Category

2020

Last patient completes final visit in SARA-INT, a Phase 2 clinical trial evaluating the efficacy of Sarconeos (BIO101) in the treatment of sarcopenia

,

/

16 December 2020

Biophytis Presents SARA-OBS study results at the Annual Conference of The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD)

,

/

14 December 2020

First Patient Enrolled in France in COVA, an International Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of COVID-19 Related Respiratory Failure

,

/

11 December 2020

Upcoming Potential Value Generating Milestones

,

/

3 December 2020

December 1st, 2020

,

/

1 December 2020

Paris Court of Appeal rules in Biophytis’ favor in connection with the dispute with NEGMA

,

/

20 November 2020

NOVEMBER 6, 2020

/

6 November 2020

Biophytis Enrolls First Patient in Brazil in COVA, a Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure

,

/

26 October 2020

October 16, 2020

,

/

18 October 2020

First US Patient Enrolled in COVA, a Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of COVID-19 Related Respiratory Failure

,

/

13 October 2020

Biophytis Trading will resume on September 30, 2020 at 3.00pm CEST

,

/

30 September 2020

Biophytis announces a € 10 million capital increase through private placement

,

/

30 September 2020